Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Apellis Pharmaceuticals (APLS) PT Lowered to $75 at Raymond James

March 3, 2025 7:56 AM EST

Raymond James analyst Steven Seedhouse lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $75.00 (from $78.00) while maintaining a Strong Buy rating.

The analyst comments "We reiterate our Strong Buy rating on APLS following 4Q24 earnings. Given sales were pre-announced during JPM (see our... More

Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 8c

February 28, 2025 7:11 AM EST

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q4 EPS of ($0.29), $0.08 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $212.5 million versus the consensus estimate of $192.9 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

... More